All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mitazalimab
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2020
Details:
The results from the study show that a large number of genes are upregulated after treatment with mitazalimab, for example PD-L1, which supports the clinical development plan for mitazalimab which includes combination studies with PD-1 inhibitors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATOR-1017
Therapeutic Area: Oncology Product Name: ATOR-1017
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
The Data Review Committee that monitors the safety of the patients in the ATOR-1017 Phase I study, has cleared the 40 mg dose and approved to start dosing with the higher dose level of 100 mg, corresponding to approximately 1.6 mg/kg.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mitazalimab
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
Alligator plans to submit a CTA, to start a Phase II clinical study. The study (OPTIMIZE-1) is an open multicenter study to evaluate the clinical effect of mitazalimab in combination with chemotherapy (mFolfirinox) in patients with spread of pancreatic cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATOR-1015
Therapeutic Area: Oncology Product Name: ATOR-1015
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2020
Details:
Interim data from up to 21 cancer patients was presented at the oncology conferences AACR and ASCO, showing a promising safety and tolerability for ATOR-1015. Currently, patients are given doses of 750 mg, approximately 12.5 mg/kg, every two weeks.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATOR-1017
Therapeutic Area: Oncology Product Name: ATOR-1017
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
Details:
US Patent Office (USPTO) has issued an approved patent for the drug candidate ATOR-1017, Alligator's wholly owned 4-1BB antibody in clinical development phase I for the treatment of disseminated cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: SAKK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 08, 2020
Details:
SAKK is the legal sponsor of the project and responsible to conduct the phase 1B trial. Oasmia’s main role in the project is to supply its formulation of docetaxel and carry the cost of the trial, which are deemed not material to Oasmia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Naptumomab estafenatox,Durvalumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2020
Details:
The Phase 1b/2 study with naptumomab in combination with the checkpoint inhibitor durvalumab in patients with advanced solid tumors aims to establish the maximum tolerated dose of the combination before advancing to a larger cohort expansion phase in the United States.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATOR-1015
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
The results of the evaluation of doses up to and including 600 mg (about 10 mg / kg) show that ATOR-1015 is well tolerated and the dose scaling has progressed to 750 mg (12.5 mg / kg).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nidanilimab,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
Details:
CAN04, an antibody targeting IL1RAP, is currently being investigated for treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC) in phase IIa clinical development.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATOR-1015
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2020
Details:
Study OC5-DB-02 (ePHex) is a 12-month randomized Phase 3 study to evaluate the efficacy and safety of Oxabact OC5 in adults and children with primary hyperoxaluria (PH) of all types.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
